{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:53:06Z","timestamp":1792068786640,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01329-1","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:17:02Z","timestamp":1787735822000},"page":"1345-1356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-6487","authenticated-orcid":false,"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"2","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-68.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","volume":"41","author":"JA Paice","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol. 2023;41(4):914\u201330.","journal-title":"J Clin Oncol"},{"key":"1329_CR3","volume-title":"Adult cancer pain guidelines, version 1. 2026","author":"National Comprehensive Cancer Network","year":"2026","unstructured":"National Comprehensive Cancer Network. Adult cancer pain guidelines, version 1. 2026. National Comprehensive Cancer Network; 2026."},{"issue":"10","key":"1329_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09883-y","volume":"33","author":"X Zhang","year":"2025","unstructured":"Zhang X, Dang DS, Sun X, Kang Y. The role of combined adjuvant therapeutic drugs in modulating opioid dosage and pain status in cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2025;33(10):841.","journal-title":"Support Care Cancer"},{"issue":"9","key":"1329_CR5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"O Corli","year":"2019","unstructured":"Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u2018real life\u2019 trial on the variability of response to opioids. Ann Oncol. 2019;30(9):1479\u201387.","journal-title":"Ann Oncol"},{"issue":"9","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(05)70317-X","volume":"6","author":"MP Davis","year":"2005","unstructured":"Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6(9):696\u2013704.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0269216310392101","volume":"25","author":"MT Fallon","year":"2011","unstructured":"Fallon MT, Laird BJ. A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliat Med. 2011;25(5):597\u2013603.","journal-title":"Palliat Med"},{"issue":"8","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.ejpain.2008.01.013","volume":"12","author":"S Mercadante","year":"2008","unstructured":"Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. Eur J Pain. 2008;12(8):1040\u20136.","journal-title":"Eur J Pain"},{"issue":"11","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1517\/14740338.2014.966077","volume":"13","author":"S Mercadante","year":"2014","unstructured":"Mercadante S. Efficacy and safety of dual opioid therapy. Expert Opin Drug Saf. 2014;13(11):1433\u20136.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1213\/01.ANE.0000099723.75548.DF","volume":"98","author":"RJ Callahan","year":"2004","unstructured":"Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth Analg. 2004;98(3):653\u20139.","journal-title":"Anesth Analg"},{"issue":"5","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0006-2952(98)00088-4","volume":"56","author":"B Ebert","year":"1998","unstructured":"Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol. 1998;56(5):553\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","volume":"223","author":"AL Gorman","year":"1997","unstructured":"Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223(1):5\u20138.","journal-title":"Neurosci Lett"},{"issue":"6","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1476-5381.2010.00967.x","volume":"161","author":"A Matsui","year":"2010","unstructured":"Matsui A, Williams JT. Activation of \u00b5-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus. Br J Pharmacol. 2010;161(6):1403\u201313.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.phrs.2009.04.002","volume":"60","author":"ML Sotgiu","year":"2009","unstructured":"Sotgiu ML, Valente M, Storchi R, et al. Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009;60(4):284\u201390.","journal-title":"Pharmacol Res"},{"key":"1329_CR15","doi-asserted-by":"crossref","unstructured":"McNicol ED, Ferguson MC, Schumann R (2017) Methadone for neuropathic pain in adults. Cochrane Database Syst. Rev. 2017:","DOI":"10.1002\/14651858.CD012499"},{"issue":"11","key":"1329_CR16","first-page":"1","volume":"20","author":"S Eum","year":"2024","unstructured":"Eum S, Zhang H, Zhu YS, et al. CYP2B6 pharmacogenomics of methadone disposition: a systemic review. Expert Opin Drug Metab Toxicol. 2024;20(11):1\u201316.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"1329_CR17","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","volume":"123","author":"ED Kharasch","year":"2015","unstructured":"Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123(5):1142\u201353.","journal-title":"Anesthesiology"},{"issue":"11","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/sj.bjc.6601365","volume":"89","author":"GR Lauretti","year":"2003","unstructured":"Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer. 2003;89(11):2027\u201330.","journal-title":"Br J Cancer"},{"issue":"11","key":"1329_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00520-004-0650-1","volume":"12","author":"S Mercadante","year":"2004","unstructured":"Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer. 2004;12(11):762\u20136.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1329_CR20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/AJP.0000000000000935","volume":"37","author":"FCN Duarte","year":"2021","unstructured":"Duarte FCN, Ferraro LHDC, Ferreira A, Sakata RK. A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain. Clin J Pain. 2021;37(6):413\u20136.","journal-title":"Clin J Pain"},{"issue":"3","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1097\/j.pain.0000000000003413","volume":"166","author":"JAM Pentiado J\u00fanior","year":"2025","unstructured":"Pentiado J\u00fanior JAM, Barbosa MM, Kubota GT, et al. METHA-NeP: effectiveness and safety of methadone for neuropathic pain: a controlled randomized trial. Pain. 2025;166(3):e123\u201332.","journal-title":"Pain"},{"issue":"8","key":"1329_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08751-5","volume":"32","author":"E Treillet","year":"2024","unstructured":"Treillet E, Perceau-Chambard E, Economos G, et al. Low-dose methadone added to another opioid for cancer pain: a multicentre prospective study. Support Care Cancer. 2024;32(8):543.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1329_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf215","volume":"30","author":"T Hasegawa","year":"2025","unstructured":"Hasegawa T, Okuyama T, Suzuki N, et al. Efficacy and safety of combining low-dose methadone with ongoing opioid treatment for uncontrolled cancer pain: an open-label single arm study. Oncologist. 2025;30(1):oyaf215.","journal-title":"Oncologist"},{"issue":"2","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/jjco\/hyae156","volume":"55","author":"T Sato","year":"2025","unstructured":"Sato T, Fukutomi A, Kawamura T, et al. Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients. Jpn J Clin Oncol. 2025;55(2):178\u201384.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","volume":"21","author":"P F\u00fcrst","year":"2018","unstructured":"F\u00fcrst P, Lundstr\u00f6m S, Klepstad P, Runesdotter S, Strang P. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med. 2018;21(2):177\u201381.","journal-title":"J Palliat Med"},{"issue":"7","key":"1329_CR26","first-page":"926","volume":"23","author":"P F\u00fcrst","year":"2020","unstructured":"F\u00fcrst P, Lundstr\u00f6m S, Klepstad P, Strang P. The use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at end of life: a national Swedish survey in specialized palliative care. J Palliat Med. 2020;23(7):926\u201332.","journal-title":"J Palliat Med"},{"issue":"3","key":"1329_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230845","volume":"15","author":"P F\u00fcrst","year":"2020","unstructured":"F\u00fcrst P, Lundstr\u00f6m S, Strang P. Methadone in Swedish specialized palliative care: is it the magic bullet in complex cancer-related pain? PLoS ONE. 2020;15(3):e0230845.","journal-title":"PLoS ONE"},{"issue":"3","key":"1329_CR28","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.jpainsymman.2024.05.022","volume":"68","author":"MSV Imkamp","year":"2024","unstructured":"Imkamp MSV, Wuertz M, Schug SA, et al. Network meta-analysis of opioid combinations for cancer pain. J Pain Symptom Manage. 2024;68(3):e191-206.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1329_CR29","first-page":"273","volume":"16","author":"KP Edmonds","year":"2020","unstructured":"Edmonds KP, Gordon MA, Dorado P, Daidone M, Trescot AM. Methadone-related QTc prolongation: a systematic review of the literature. J Opioid Manag. 2020;16(4):273\u201381.","journal-title":"J Opioid Manag"},{"issue":"4","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","volume":"15","author":"R Chou","year":"2014","unstructured":"Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence. J Pain. 2014;15(4):321\u201337.","journal-title":"J Pain"},{"issue":"6","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/jpm.2012.0612","volume":"16","author":"SR Salpeter","year":"2013","unstructured":"Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med. 2013;16(6):616\u201322.","journal-title":"J Palliat Med"},{"issue":"3","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00000542-200703000-00022","volume":"106","author":"JR Holtman","year":"2007","unstructured":"Holtman JR, Wala EP. Characterization of morphine-induced hyperalgesia in male and female rats. Anesthesiology. 2007;106(3):563\u201371.","journal-title":"Anesthesiology"},{"key":"1329_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2016.06.025","volume":"65","author":"J Haumann","year":"2016","unstructured":"Haumann J, Geurts JW, van Kuijk SM, et al. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. Eur J Cancer. 2016;65:121\u20139.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1329_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080997","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, Stahl SM, De Martin S, et al. Pharmacological comparative characterization of REL-1017 (esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-D-aspartate receptors. Pharmaceuticals (Basel). 2022;15(8):997.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1329_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0022-3565(24)37037-5","volume":"283","author":"N Shimoyama","year":"1997","unstructured":"Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE. d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther. 1997;283(2):648\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","volume":"39","author":"G Bernstein","year":"2019","unstructured":"Bernstein G, Davis K, Mills C, et al. Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies. J Clin Psychopharmacol. 2019;39(3):226\u201334.","journal-title":"J Clin Psychopharmacol"},{"key":"1329_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2147\/JPR.S315585","volume":"14","author":"MM Aman","year":"2021","unstructured":"Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) best practices and guidelines for the interventional management of cancer-associated pain. J Pain Res. 2021;14:1141\u201367.","journal-title":"J Pain Res"},{"key":"1329_CR38","doi-asserted-by":"crossref","unstructured":"Mcguirt AF (2024) Brezing CAOpioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention. Am J Drug Alcohol Abuse 50:132\u2013138","DOI":"10.1080\/00952990.2023.2292012"},{"issue":"5","key":"1329_CR39","volume":"14","author":"CH Maeng","year":"2024","unstructured":"Maeng CH, Kim DY, Yoon J, et al. Combination opioid therapy for cancer pain (PROSPERO protocol). BMJ Open. 2024;14(5):e083025.","journal-title":"BMJ Open"},{"issue":"2","key":"1329_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0304-3959(97)00093-6","volume":"73","author":"FB Ross","year":"1997","unstructured":"Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain. 1997;73(2):151\u20137.","journal-title":"Pain"},{"issue":"3","key":"1329_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00520-006-0146-2","volume":"15","author":"E Prommer","year":"2007","unstructured":"Prommer E. Levorphanol: the forgotten opioid. Support Care Cancer. 2007;15(3):259\u201364.","journal-title":"Support Care Cancer"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01329-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:00:00Z","timestamp":1789048800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01329-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sebastiano Mercadante has no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM: conceptualization\u00a0and writing.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}